These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 16219399)

  • 1. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits.
    Pal R; Yu Q; Wang S; Kalyanaraman VS; Nair BC; Hudacik L; Whitney S; Keen T; Hung CL; Hocker L; Kennedy JS; Markham P; Lu S
    Vaccine; 2006 Feb; 24(8):1225-34. PubMed ID: 16219399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost".
    Wang Z; Wang SX; Liu SY; Bao ZY; Zhuang DM; Li L; Zhang CH; Zhang L; Li JY; Lu S
    Chin Med J (Engl); 2009 Oct; 122(19):2339-45. PubMed ID: 20079137
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost.
    Shinoda K; Xin KQ; Kojima Y; Saha S; Okuda K; Okuda K
    Clin Immunol; 2006 Apr; 119(1):32-7. PubMed ID: 16458074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.
    Cristillo AD; Wang S; Caskey MS; Unangst T; Hocker L; He L; Hudacik L; Whitney S; Keen T; Chou TH; Shen S; Joshi S; Kalyanaraman VS; Nair B; Markham P; Lu S; Pal R
    Virology; 2006 Mar; 346(1):151-68. PubMed ID: 16325880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.
    Rollman E; Mathy N; Bråve A; Boberg A; Kjerrström A; van Wely C; Engström G; Johansson S; Aperia K; Eriksson LE; Benthin R; Ertl P; Heeney J; Hinkula J; Voss G; Wahren B
    Vaccine; 2007 Mar; 25(11):2145-54. PubMed ID: 17254672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
    Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
    Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
    Bower JF; Li Y; Wyatt R; Ross TM
    Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA-VLP prime-boost intra-nasal immunization induces cellular and humoral anti-HIV-1 systemic and mucosal immunity with cross-clade neutralizing activity.
    Buonaguro L; Devito C; Tornesello ML; Schröder U; Wahren B; Hinkula J; Buonaguro FM
    Vaccine; 2007 Aug; 25(32):5968-77. PubMed ID: 17629365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of immune responses to an HIV gp120 DNA vaccine by fusion to TNF alpha cDNA.
    Nimal S; Heath AW; Thomas MS
    Vaccine; 2006 Apr; 24(16):3298-308. PubMed ID: 16464521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.
    Radaelli A; Bonduelle O; Beggio P; Mahe B; Pozzi E; Elli V; Paganini M; Zanotto C; De Giuli Morghen C; Combadière B
    Vaccine; 2007 Mar; 25(11):2128-38. PubMed ID: 17241705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines.
    Wang S; Chou TH; Hackett A; Efros V; Wang Y; Han D; Wallace A; Chen Y; Hu G; Liu S; Clapham P; Arthos J; Montefiori D; Lu S
    Hum Vaccin Immunother; 2017 Dec; 13(12):2996-3009. PubMed ID: 28933684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.
    Yu S; Feng X; Shu T; Matano T; Hasegawa M; Wang X; Ma H; Li H; Li Z; Zeng Y
    Vaccine; 2008 Nov; 26(48):6124-31. PubMed ID: 18812199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
    Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
    J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 Env vaccine comprised of electroporated DNA and protein co-administered with Talabostat.
    Cristillo AD; Galmin L; Restrepo S; Hudacik L; Suschak J; Lewis B; Draghia-Akli R; Aziz N; Weiss D; Markham P; Pal R
    Biochem Biophys Res Commun; 2008 May; 370(1):22-6. PubMed ID: 18329382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent antibody and T cell responses induced by HIV-1 DNA vaccine delivered by electroporation.
    Cristillo AD; Weiss D; Hudacik L; Restrepo S; Galmin L; Suschak J; Draghia-Akli R; Markham P; Pal R
    Biochem Biophys Res Commun; 2008 Feb; 366(1):29-35. PubMed ID: 18036339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.
    Gómez CE; Nájera JL; Jiménez EP; Jiménez V; Wagner R; Graf M; Frachette MJ; Liljeström P; Pantaleo G; Esteban M
    Vaccine; 2007 Apr; 25(15):2863-85. PubMed ID: 17113200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3.
    Cristillo AD; Lisziewicz J; He L; Lori F; Galmin L; Trocio JN; Unangst T; Whitman L; Hudacik L; Bakare N; Whitney S; Restrepo S; Suschak J; Ferrari MG; Chung HK; Kalyanaraman VS; Markham P; Pal R
    Virology; 2007 Sep; 366(1):197-211. PubMed ID: 17499328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing immune responses against HIV-1 DNA vaccine by coinoculating IL-6 expression vector.
    Jiang W; Jin N; Cui S; Li Z; Zhang L; Wang H; Han W
    J Virol Methods; 2006 Sep; 136(1-2):1-7. PubMed ID: 16793146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.